CONTACT



INNOVATION VENTURES AVAILABLE TECHNOLOGIES CO

CONTACT US

Permalink

Request Information

Antibodies That Stimulate Nk Cell-Mediated Cytotoxicity

Tech ID: 33603 / UC Case 2021-220-0

TECHNOLOGY DESCRIPTION

Current cancer therapies often have limitations such as off-target effects, development of resistance, and limited efficacy against certain cancer types. There is a pressing need for therapies that can specifically target cancer cells and enhance the body's natural immune response against these malignant cells.

The inventors have developed a bispecific antibody therapy that targets Natural Cytotoxicity Triggering Receptors (NCR1, NCR3) or CD-16 on Natural Killer (NK) cells and a specific antigen on the cancer cell. This therapy will enhance the cytotoxic response of NK cells towards the cancer cells, leading to targeted cell death. Bispecific targeting of NCR3 presents a novel opportunity to potently activate NK cells, thereby enhancing the antitumor immune responses.

RELATED MATERIALS

► A functional mammalian display screen identifies rare antibodies that stimulate NK cell-mediated cytotoxicity - 08/03/2021

DATA AVAILABILITY

The inventors have developed a functional screen to identify antibodies that can activate NK cells. From this screen, antibodies specific for NCR1, NCR3, and CD-16 were identified. These antibodies bound with high affinity to NK cells, and the subsequent development of bispecific antibody constructs showed successful redirection of NK cell-mediated cytotoxicity towards CD20+ B cell lymphomas and HER+ breast cancer cells.

PATENT STATUS

Country	Туре	Number	Dated	Case
Japan	Published Application	2024-522180	06/11/2024	2021-220

Gemma E. Rooney Gemma.Rooney@ucsf.edu tel: 415-625-9093.



OTHER INFORMATION

KEYWORDS NK Cell, Bispecific Antibody, NCR1, NCR3, CD16

CATEGORIZED AS

Medical

- Disease: Cancer
- Therapeutics

RELATED CASES 2021-220-0

ADDRESS

UCSF

Innovation Ventures

600 16th St, Genentech Hall, S-272,

San Francisco,CA 94158

CONTACT

Tel: innovation@ucsf.edu

https://innovation.ucsf.edu Fax: CONNECT Follow in Connect

© 2024, The Regents of the University of California Terms of use Privacy Notice